Gilead Sciences Acquires CymaBay for $4.3 Billion, Expanding Liver Disease Portfolio
TL;DR
Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with potential blockbuster sales. The deal provides Gilead with CymaBay's lead experimental drug, seladelpar, which is under FDA review for potential treatment of primary biliary cholangitis. This acquisition comes as Gilead seeks growth beyond its core HIV business and amidst recent setbacks in clinical trials for other drugs.
Topics:businessbusiness-healthcare#acquisition#business-healthcare#cymabay-therapeutics#experimental-drug#gilead-sciences#liver-disease-treatment
- Gilead to buy CymaBay for $4.3 bln in bets on liver disease treatment Reuters
- CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal The Wall Street Journal
- CymaBay's stock surges as Gilead reaches $4.3 billion deal for liver-drug maker MarketWatch
- Gilead to Buy CymaBay, Lead Liver Disease Asset Seladelpar for $4.3B BioSpace
- Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics Yahoo Finance
Want the full story? Read the original reporting
Read on Reuters